The Food and Drug Administration said it will make a ruling on Biogen's Alzheimer's drug this summer.

Closing Bell

FDA Announces Biogen Alzheimer's Drug Decision To Come This Summer

And we now know when the F D A is gonna make its decision on whether to approve a new Alzheimer's drugs shown to slow the disease's progression. Biotech company Biogen and Japanese Pharma giant a size saying the agency is reviewing its data and will make a ruling in early July Biogen shares down fractionally today. But the FDA already approving the drug in January on a special basis, but it's not yet widely accessible to patients Medicare and Medicaid saying at the time that they would offer more coverage for the drug once it gets full approval from the FDA Clinical trials, showing the drugs slow down Alzheimer's progression by 27% but does have a risk of brain swelling and bleeding Medicare and Medicaid coverage will be helpful if not necessary for Alzheimer patients and their families. That's because the drug costs a whopping $26,500 a year. The FDA targeting a July six deadline.